Literature DB >> 32784070

Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia.

Kotaro Miyao1, Seitaro Terakura2, Fumihiko Kimura3, Takaaki Konuma4, Koichi Miyamura5, Masamitsu Yanada6, Shinichi Kako7, Satoko Morhishima8, Naoyuki Uchida9, Takashi Toya10, Yukiyasu Ozawa5, Takahiro Fukuda11, Masatsugu Tanaka12, Masashi Sawa13, Satoru Takada14, Shuro Yoshida15, Takafumi Kimura16, Tatsuo Ichinohe17, Yoshiko Atsuta18, Junya Kanda19.   

Abstract

The outcomes of 7/8 allele-matched unrelated bone marrow transplantation (7/8 UBMT) and umbilical cord blood transplantation (UCBT) have been improving. We retrospectively analyzed adults with acute leukemia who underwent their first 7/8 UBMT or UCBT in Japan. Between January 2008 and December 2017, a total of 4150 patients were recorded, including 488 who underwent 7/8 UBMT and 3662 who underwent UCBT. Only 32 patients with 7/8 UBMT had graft-versus-host-disease (GVHD) high-risk HLA mismatched pairs. Overall survival at 3 years was 54% for 7/8 the UBMT group and 46% for the UCBT group, a nonsignificant difference in multivariate analysis (hazard ratio [HR], 1.01; 95% confidence interval [CI], .88 to 1.17; P = .89). The 7/8 UBMT and UCBT groups showed a similar nonrelapse mortality rate (HR, 1.16; 95% CI, .96 to 1.45; P = .16) and relapse rate (HR, .85; 95% CI, .71 to 1.02; P = .08). However, the UCBT group had a lower risk of grade II-IV acute GVHD (HR, .76; 95% CI, .65 to .88; P < .001) and chronic GVHD (HR, .77; 95% CI, .66- .91; P = .002) compared with the 7/8 UBMT group. In stratified analyses combining disease risk with conditioning intensity, 7/8 UBMT showed superior overall survival to UCBT in standard risk and myeloablative conditioning (HR, .72; 95% CI, .56 to .93; P = .014). Both 7/8 UBMT and UCBT are appropriate alternative donor procedures. The stem cell source can be selected on the basis of disease risk, patient tolerability, or concerns regarding GVHD.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute leukemia; Alternative donor; Umbilical cord blood transplantation; Unrelated bone marrow transplantation

Mesh:

Year:  2020        PMID: 32784070     DOI: 10.1016/j.bbmt.2020.08.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

1.  Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.

Authors:  Takaaki Konuma; Jun Ooi; Hitomi Nagayama; Akira Tomonari; Nobuhiro Tsukada; Seiko Kato; Toshiro Kawakita; Masamichi Isobe; Maki Monna-Oiwa; Arinobu Tojo; Tohru Iseki; Satoshi Takahashi
Journal:  Ann Hematol       Date:  2021-09-30       Impact factor: 3.673

2.  Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.

Authors:  Takaaki Konuma; Shohei Mizuno; Tadakazu Kondo; Yasuyuki Arai; Naoyuki Uchida; Satoshi Takahashi; Masatsugu Tanaka; Takuro Kuriyama; Shigesaburo Miyakoshi; Makoto Onizuka; Shuichi Ota; Yasuhiro Sugio; Yasushi Kouzai; Toshiro Kawakita; Hikaru Kobayashi; Yukiyasu Ozawa; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Blood Cancer J       Date:  2022-05-25       Impact factor: 9.812

3.  Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior OS for patients with long-term survival.

Authors:  Guangyu Sun; Baolin Tang; Kaidi Song; Yue Wu; Meijuan Tu; Xiang Wan; Wen Yao; Liangquan Geng; Ping Qiang; Xiaoyu Zhu
Journal:  Stem Cell Res Ther       Date:  2022-10-09       Impact factor: 8.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.